One of the more alarming instances of immunogenicity leading to life-threatening safety concerns is pure red cell aplasia (PRCA) in chronic renal failure patients treated with recombinant human erythropoietin (EPO). The gene discussed is EPO; the disease is Pure red cell aplasia.